Highlights
- 1Transplantation and cellular therapy · 2023
- 2
- 3
Publications
29 publications
Funding
7 grants
Active
7 grants- KPCOG NCTN Network Group Operations CenterNational Cancer Institute · 2026–2032 · via Children's Oncology GroupU10CA180886-12
- PIPhase 2 study of Tovorafenib (Day 101) in Relapsed and Refractory Langerhans Cell HistiocytosisMedical College of Virginia Foundation · 2025–2027MCVF 252199-02
- MPIClinical and Translational Science Center- Institutional CTSC Internal Funding UL1CTSC Cost Share · 2022–2027UL1TR002384-06
- PIBiomarkers of response in primary mediastinal B-cell lymphoma: Defining tumor microenvironment signaturesHyundai Hope on Wheels Foundation · 2024–2026HHWF 240412-02
- KPWWWW Foundation, Inc: COGFndn_NY018_2026_QuadW_CSBAO_Tissue IncentivesWWWW Foundation INC dba QuadW · 2025–2026 · via Children's Oncology GroupCOG 264538
- MPIMolecular Characterization of Primary Mediastinal B-cell Lymphoma to Identify Novel BiomarkersNational Cancer Institute · 2025–2026 · via Public Health InstituteUG1CA233249-06
- MPIRisk Stratification using Tumor Microenviroment Signatures in Hodgkin LymphomaChildren's Oncology Group · 2022–2026COG 222649-02
Clinical research
5 studies
Active
4 studies- PIReal-World Experiences In Rare Pediatric, Adolescent, and Young Adult Lymphoma The "Umbrella Study"Ann & Robert H Lurie Childrens Hospital of Chicago · OPEN TO ACCRUAL (as of 2026)
- PINCT05828069Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell HistiocytosisPHASE2 · Children's Oncology Group · OPEN TO ACCRUAL (as of 2025)Recurrent Langerhans Cell Histiocytosis; Refractory Langerhans Cell Histiocytosis
- PINCT05675410A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin LymphomaPHASE3 · Children's Oncology Group · OPEN TO ACCRUAL (as of 2025)Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
- PIMolecular analysis of lymphomas in children adolescents, and adultsWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
Completed & closed trials (1)
- PINCT04759586A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaPHASE3 · Children's Oncology Group · CLOSED TO ACCRUAL (as of 2025)Primary Mediastinal Large B-Cell Lymphoma
News mentions
2 mentionsView all WCM news ↗
- Awards & Honors: November 2025December 1, 2025
Awards, honors and achievements for the month of November.
- Ritu Banga Healthcare Disparities Research Awards Support Innovative ScienceMay 22, 2025
Four Weill Cornell Medicine investigators received the Ritu Banga Healthcare Disparities Research Awards, recognizing innovative research that will help close care gaps in clinical settings.